Search

Scholarly Works (1 results)

Article
Peer Reviewed

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.

Munster, Pamela;
Lin, NU;
Winer, EP;
Wheatley, D;
Carey, LA;
Houston, S;
Mendelson, D;
Frakes, L;
Kelly, S;
Garcia, AA

UC San Francisco Previously Published Works (2012)

Afatinib is an oral, ErbB family blocker, which covalently binds and irreversibly blocks all kinase-competent ErbB family members. This phase II, open-label, single-arm study explored afatinib activity in human epidermal growth factor receptor 2 (HER2)-pos